摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-溴-1,3-二氢-3-(S)-甲基-5-(吡啶-2'-基)-2H-1,4-苯并二氮杂-2-酮 | 136295-75-5

中文名称
7-溴-1,3-二氢-3-(S)-甲基-5-(吡啶-2'-基)-2H-1,4-苯并二氮杂-2-酮
中文别名
——
英文名称
7-bromo-1,3-dihydro-3(S)-methyl-5-(2'-pyridyl)-2H-1,4-benzodiazepin-2-one
英文别名
7-bromo-1,3-dihydro-3(S)-methyl-5-(pyrid-2'-yl)-2H-1,4-benzodiazepin-2-one;(S)-7-bromo-3-methyl-5-(pyridin-2’-yl)-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one;(S)-7-bromo-3-methyl-5-pyridin-2-yl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;(3S)-7-Bromo-1,3-dihydro-3-methyl-5-(2-pyridinyl)-2H-1,4-benzodiazepin-2-one;(3S)-7-bromo-3-methyl-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one
7-溴-1,3-二氢-3-(S)-甲基-5-(吡啶-2'-基)-2H-1,4-苯并二氮杂-2-酮化学式
CAS
136295-75-5
化学式
C15H12BrN3O
mdl
——
分子量
330.184
InChiKey
WJIMWXPMEGQBDG-VIFPVBQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    20
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    54.4
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-溴-1,3-二氢-3-(S)-甲基-5-(吡啶-2'-基)-2H-1,4-苯并二氮杂-2-酮 在 potassium fluoride 、 palladium diacetate 作用下, 以 四氢呋喃 为溶剂, 反应 2.0h, 以82%的产率得到(S)-3-methyl-5-(pyridin-2-yl)-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one
    参考文献:
    名称:
    An efficient debromination technique using PMHS with a number of ligands containing different functional groups
    摘要:
    DOI:
    10.24820/ark.5550190.p011.712
  • 作为产物:
    参考文献:
    名称:
    某些具有5-Pyrido-1,4-benzodiazepin-4-ones的二氮配体的Rh(I)催化配合物的合成和性能
    摘要:
    制备了一系列双齿氮配体(3-8)及其[Rh(I)(NBD)(NN)] ClO 4络合物11-14(NBD-降冰片二烯,NN-二氮配体)。报道了4及其催化配合物12的构象性质和稳定性。比较了配合物11和12在环己烷氢化中的催化活性与22(一种包含2,2'-联吡啶基作为“标准”配体的配合物)的催化活性。据报道手性配体5,6及其Rh(I)复合物13,14的手性数据。
    DOI:
    10.1016/s0040-4020(01)87141-6
点击查看最新优质反应信息

文献信息

  • Synthesis and properties of some Rh(I) catalytic complexes with dinitrogen ligands derived from 5-Pyrido-1,4-benzodiazepin-4-ones
    作者:Predrag Čudić、Branimir Klaić、Zlata Raza、Dragan Šepac、Vitomir Šunjić
    DOI:10.1016/s0040-4020(01)87141-6
    日期:1991.1
    A series of bidentate nitrogen ligands (3–8), and their [Rh (I) (NBD) (N-N)] ClO4 complexes 11–14 (NBD-norbornadiene, N-N-dinitrogen ligand) were prepared. Conformational properties and stability of 4 and its catalytic complex 12 were reported. Catalytic activity of complexes 11 and 12 in hydrogenation of cyclohexane is compared with 22, a complex that contains 2,2′-bipyridyl as the “standard” ligand
    制备了一系列双齿氮配体(3-8)及其[Rh(I)(NBD)(NN)] ClO 4络合物11-14(NBD-降冰片二烯,NN-二氮配体)。报道了4及其催化配合物12的构象性质和稳定性。比较了配合物11和12在环己烷氢化中的催化活性与22(一种包含2,2'-联吡啶基作为“标准”配体的配合物)的催化活性。据报道手性配体5,6及其Rh(I)复合物13,14的手性数据。
  • Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
    申请人:Cook M. James
    公开号:US20060003995A1
    公开(公告)日:2006-01-05
    The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-XXI and a pharmaceutically-acceptable carrier.
    本发明提供了使用立体特异性苯二氮卓类衍生物、它们的盐和前药治疗焦虑症或癫痫发作障碍的组合物和方法,该方法具有减少酒精渴望的副作用,同时减少酒精成瘾者的镇静、催眠、肌肉松弛和共济失调副作用。本发明还提供了用于治疗焦虑症和癫痫发作障碍的药物组合物,包括具有化学结构由任何一种I-XXI式表示的化合物、前药或盐,以及一种药学上可接受的载体。
  • SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES
    申请人:Cook James M.
    公开号:US20100261711A1
    公开(公告)日:2010-10-14
    In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of seizures. The preferred embodiments of the present invention further relate to methods of treatment and pharmaceutical compositions using benzodiazepine derivatives that provide suppression, alleviation and prevention of seizures with reduced sedative and ataxic side effects.
    在优选实施方式中,本发明提供了用于抑制、缓解和预防癫痫发作的治疗方法和药物组合物。本发明的优选实施方式进一步涉及使用苯二氮䓬类衍生物的治疗方法和药物组合物,该类衍生物在减少镇静和共济失调副作用的同时提供了抑制、缓解和预防癫痫发作的效果。
  • STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS
    申请人:Cook James M.
    公开号:US20100004226A1
    公开(公告)日:2010-01-07
    The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-IV, VI-XI, XV-XVIII and XX-XXI and a pharmaceutically-acceptable carrier.
    本发明提供了立体特异性苯二氮平衍生物、其盐和前药的组合物及使用方法,用于治疗焦虑或惊厥性疾病,在人类酗酒者中具有减少酒精渴望的副作用,以及同时减少镇静、催眠、肌肉松弛和共济失调的副作用。本发明进一步提供了用于治疗需要该类治疗的焦虑和惊厥性疾病患者的药物组合物,包括具有化学结构的化合物、前药或盐Formula I-IV、VI-XI、XV-XVIII和XX-XXI中的任意一个,并且是药学可接受的载体。
  • Selective Agents for Pain Suppression
    申请人:Cook James
    公开号:US20100317619A1
    公开(公告)日:2010-12-16
    In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of the often chronic, severe and debilitating pain that can accompany inflammatory diseases and neuropathic insults, pain that is often unresponsive to conventional analgesic treatment. The preferred embodiments of the present invention further relate to methods of treatment and pharmaceutical compositions using benzodiazepine derivatives that provide suppression, alleviation and prevention of neuropathic pain, migraine-related pain and inflammatory pain with reduced sedative and ataxic side effects.
    在首选实施例中,本发明提供了治疗方法和药物组合物,用于抑制、缓解和预防伴随炎症性疾病和神经病变的常见、严重和令人痛苦的慢性疼痛,这种疼痛通常对常规镇痛治疗无效。本发明的首选实施例还涉及使用苯二氮平衍生物的治疗方法和药物组合物,其提供了抑制、缓解和预防神经病理性疼痛、偏头痛相关疼痛和炎症性疼痛的效果,并减少了镇静和共济失调的副作用。
查看更多